These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25731800)

  • 1. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year.
    Cornell LD; Schinstock CA; Gandhi MJ; Kremers WK; Stegall MD
    Am J Transplant; 2015 May; 15(5):1293-302. PubMed ID: 25731800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.
    Schinstock CA; Bentall AJ; Smith BH; Cornell LD; Everly M; Gandhi MJ; Stegall MD
    Am J Transplant; 2019 Jun; 19(6):1671-1683. PubMed ID: 30412654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
    Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
    Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient.
    Chehade H; Rotman S; Matter M; Girardin E; Aubert V; Pascual M
    Pediatrics; 2015 Feb; 135(2):e551-5. PubMed ID: 25624380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early subclinical inflammation correlates with outcomes in positive crossmatch kidney allografts.
    Dean PG; Park WD; Cornell LD; Schinstock CA; Stegall MD
    Clin Transplant; 2016 Aug; 30(8):925-33. PubMed ID: 27225518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year outcomes in living donor kidney transplants with a positive crossmatch.
    Bentall A; Cornell LD; Gloor JM; Park WD; Gandhi MJ; Winters JL; Chedid MF; Dean PG; Stegall MD
    Am J Transplant; 2013 Jan; 13(1):76-85. PubMed ID: 23072543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
    Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.
    Tsuji T; Yanai M; Itami H; Ishii Y; Akimoto M; Fukuzawa N; Harada H; Fukasawa Y
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():26-30. PubMed ID: 26031582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection.
    Kikić Ž; Kainz A; Kozakowski N; Oberbauer R; Regele H; Bond G; Böhmig GA
    Clin J Am Soc Nephrol; 2015 Aug; 10(8):1435-43. PubMed ID: 26071493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients.
    Bagnasco SM; Zachary AA; Racusen LC; Arend LJ; Carter-Monroe N; Alachkar N; Nazarian SM; Lonze BE; Montgomery RA; Kraus ES
    Transplantation; 2014 Feb; 97(4):440-5. PubMed ID: 24531821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study.
    Kim DG; Lee J; Park Y; Kim MS; Jeong HJ; Kim SI; Kim YS; Kim BS; Huh KH
    BMC Nephrol; 2019 Dec; 20(1):456. PubMed ID: 31818254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of C3d-fixing, preformed donor-specific antibodies in crossmatch-positive living kidney transplantation.
    Miyake K; Okumi M; Kakuta Y; Unagami K; Furusawa M; Ishida H; Tanabe K
    Transpl Immunol; 2019 Dec; 57():101230. PubMed ID: 31398461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
    Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
    Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement inhibition in HLA-incompatible kidney transplants: persisting antibody-mediated injury despite marked decrease of clinical ABMR.
    Loupy A; Viglietti D; Mengel M
    Am J Transplant; 2015 May; 15(5):1139-40. PubMed ID: 25731892
    [No Abstract]   [Full Text] [Related]  

  • 20. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.
    Pongpirul W; Chancharoenthana W; Pongpirul K; Leelahavanichkul A; Kittikowit W; Jutivorakool K; Nonthasoot B; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K; Townamchai N
    Nephrology (Carlton); 2018 Feb; 23(2):169-174. PubMed ID: 27888573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.